![John Lambert](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Fortune : - $ au 31/05/2026
John M.
Lambert is currently Director at Defence Therapeutics Inc, starting in 2026.
Formerly, Dr. Lambert was Chief Scientific Officer & Executive VP-Research at ImmunoGen, Inc. from 2011 to 2015 and Assistant Professor-Pathology at Dana-Farber Cancer Institute, Inc. Education includes a doctorate from the University of Cambridge and an undergraduate degree from Christ's College (United Kingdom).
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 01/06/2026 | 0 ( -.--% ) | - $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| DEFENCE THERAPEUTICS INC. | Directeur/Membre du Conseil | 01/06/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
Dana-Farber Cancer Institute, Inc.
 Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Corporate Officer/Principal | - |
| IMMUNOGEN, INC. | Directeur Technique/Scientifique/R&D | 05/01/2015 |
Actives
Inactives
Sociétés cotées
Entreprise privées
| Entreprise privées | 5 |
|---|---|
ImmunoGen, Inc.
 ImmunoGen, Inc. BiotechnologyHealth Technology Develops anticancer therapeutics | Health Technology |
Dana-Farber Cancer Institute, Inc.
Dana-Farber Cancer Institute, Inc. Hospital/Nursing ManagementHealth Services Provides treatment to cancer patients | Health Services |
University of Cambridge
 University of Cambridge Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Christ's College (United Kingdom)
 Christ's College (United Kingdom) Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Defence Therapeutics Inc
 Defence Therapeutics Inc Pharmaceuticals: MajorHealth Technology Engages in the research and development of anti-body drug conjugates | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national
